TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06294548
Drug: Valemetostat
Normalized name: Valemetostat
DrugBank: Valemetostat (DB18314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).
Study: NCT06294548
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
Study: NCT06294548
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
Study: NCT04960124
Drug: JNJ-42847922
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
Study: NCT06524583
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.1 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
Study: NCT05705336
Drug: Tranexamic Acid Oral Product
Normalized name: tranexamic acid Oral Product
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
Study: NCT05305924
Drug: Fulvestrant Run-In
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
Study: NCT00002432
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05601271
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 100 to 300 mg a day for 3 months
Study: NCT00304668
Drug: dapivirine (TMC120) vaginal gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04105062
Drug: LS301
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
Study: NCT02785224
Drug: Vasopressin Steroids Epinephrine
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
Study: NCT04985812
Drug: JNJ-67484703
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-67484703.
Study: NCT04988256
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description
Study: NCT04988256
Drug: Methylprednisolone and Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
Study: NCT05362513
Drug: Ivermectin Tablets
Normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B received a single dose of oral ivermectin 200 mcg per kg
Study: NCT05362513
Drug: Permethrin Cream
Normalized name: Permethrin Cream
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A received Permethrin 5% twice with a one-week interval.
Study: NCT04705402
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes.
Study: NCT05554406
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT05554406
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05554406
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05554406
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05554406
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04634552
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered SC until disease progression.
Study: NCT05646381
Drug: Pelacarsen (TQJ230) 80mg
Normalized name: Pelacarsen
DrugBank: Pelacarsen (DB16284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen (TQJ230) 80mg
Study: NCT04951609
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of seltorexant.
Study: NCT04619420
Drug: JNJ-63733657
Normalized name: Immunoglobulin G1, anti-(human phosphorylated tau protein) (human-Mus musculus monoclonal JNJ-63733657 γ1-chain), disulfide with human-Mus musculus monoclonal JNJ-63733657 κ-chain, dimer
DrugBank: Posdinemab (DB18941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-63733657 low or high dose will be administered by IV infusion.
Study: NCT05985915
Drug: Ianalumab (VAY736)
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
Study: NCT04705402
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
Study: NCT06459193
Drug: Trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg tab once daily
Study: NCT05991323
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection solution; subcutaneous
Study: NCT04872634
Drug: GC
Normalized name: EGC
DrugBank: Epigallocatechin (DB03823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour.
Study: NCT05739981
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 IV
Study: NCT05739981
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5-6 IV
Study: NCT05739981
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
Study: NCT04214249
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via continuous IV infusion
Study: NCT04214249
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04214249
Drug: Idarubicin Hydrochloride
Normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05640271
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 80 mg IV dose (one time per patient)
Study: NCT05879978
Drug: Ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezabenlimab
Study: NCT05483400
Drug: Tiragolumab and atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
Study: NCT04978012
Drug: Fluzoparib and Camrelizumab
Normalized name: cytarabine and daunorubicin
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
Study: NCT04550104
Drug: Olaparib Oral Tablet [Lynparza]
Normalized name: olaparib Oral Tablet [Lynparza]
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT04550104
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04550104
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg iv infusion
Study: NCT06277336
Drug: Apelin Low Dose
Normalized name: ethinyl estradiol
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 1 nmol/min (60ml per h)
Study: NCT06277336
Drug: Apelin High Dose
Normalized name: high-density polyethylene
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 10 nmol/min (60ml per h)
Study: NCT06277336
Drug: Selected Apelin Dose
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study infusions (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours based on the best performing apelin dose (from Low Dose or High Dose) in healthy volunteers corresponding to one of the following options:~  1. at an infusion rate of 1 nmol/min (60ml per h) OR~ 2. at an infusion rate of 10 nmol/min (60ml per h)~In case both apelin dosis performed equally well in the healthy volunteers population the lower dose will be selected.
Study: NCT04232800
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
Study: NCT05690945
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
Study: NCT00249119
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05212597
Drug: Sacubitril-valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg\~100mg twice daily
Study: NCT05212597
Drug: Amlodipine-losartan
Normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
Study: NCT05286827
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
Study: NCT04774393
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04774393
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04774393
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05998408
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
Study: NCT05706753
Drug: Milvexian
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian will be administered orally.
Study: NCT05706753
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered orally.
Study: NCT05706753
Drug: Ethinylestradiol
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol will be administered orally.
Study: NCT05706753
Drug: Drospirenone
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone will be administered orally.
Study: NCT06421675
Drug: Elranatamab injection
Normalized name: elranatamab Injection
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
Study: NCT06082986
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
Study: NCT06374017
Drug: Normal saline, Lidocaine, dexmetomidine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.
Study: NCT05841758
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
Study: NCT05095207
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
Study: NCT06111443
Drug: Dapagliflozin 10 mg [Farxiga]
Normalized name: dapagliflozin 10 MG [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
Study: NCT05095207
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg orally daily, day 1 to 28.
Study: NCT04788043
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
Study: NCT04788043
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV infusion
Study: NCT00006196
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05564806
Drug: YH004
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
Study: NCT05528510
Drug: Guselkumab Dose 1
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 1) will be administered as SC injection.
Study: NCT05528510
Drug: Guselkumab Dose 2
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 2) will be administered as SC injection.
Study: NCT05528510
Drug: Guselkumab Dose 3
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 3) will be administered as SC injection.
Study: NCT04232657
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
Study: NCT04232657
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
Study: NCT05111574
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06534190
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy treatment with Nivolumab
Study: NCT06534190
Drug: Cetrelimab
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy treatment with cetrelimab
Study: NCT05784441
Drug: JNJ-90009530
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
Study: NCT06533865
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
Study: NCT06072898
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
Study: NCT05773950
Drug: fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.
Study: NCT06696443
Drug: Suzetrigine
Normalized name: Suzetrigine
DrugBank: Suzetrigine (DB18927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04713930
Drug: JNJ-61393215
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61393215 will be administered orally.
Study: NCT05003986
Drug: Sparsentan
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population 1: 800 mg Sparsentan (oral suspension)
Study: NCT05003986
Drug: Sparsentan
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population 2: 400 mg Sparsentan (oral suspension)
Study: NCT05003986
Drug: Sparsentan
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Population 3: 400 mg Sparsentan (tablets)
Study: NCT04388501
Drug: Milvexian
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.